Holen Sie sich die Stockscreener-App
177.34
3.50%
-6.44
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BIIB?
Forum
Prognose
Aktiensplit
Biogen Inc Aktie (BIIB) Neueste Nachrichten
Biogen’s Apellis Deal Reshapes Growth Outlook And Valuation Story - Yahoo Finance Singapore
Stifel Maintains Biogen(BIIB.US) With Buy Rating, Maintains Target Price $214 - Moomoo
15,051 Shares in Biogen Inc. $BIIB Bought by Element Squared LLC - MarketBeat
Biogen (NASDAQ: BIIB) plans tender offer to acquire Apellis (APLS); materials pending - Stock Titan
Biogen (BIIB) CAO Sean Godbout nets shares from RSU vesting and tax withholding - Stock Titan
Deal Dispatch: McCormick, Unilever Merge, Sysco Acquires Jetro Restaurant Depot For $29 Billion, QVC Considers Bankruptcy - Benzinga
Biogen to acquire Apellis in $5.6 billion deal - Ophthalmology Times
Biogen Inc stock: Plunges to $177.34 – What it means for you - AD HOC NEWS
Rx Rundown: Eli Lilly, Blackstone, Biogen and more - Medical Marketing and Media
Nisa Investment Advisors LLC Sells 9,121 Shares of Biogen Inc. $BIIB - MarketBeat
Apellis Pharmaceuticals (APLS) hits 2-year high on 140% upside from Biogen merger - MSN
Weekly Buzz: SPRY Gains FDA Nod; EU Expands Kerendia Label; LLY Acquires CNTA; BIIB Snaps Up APLS - RTTNews
Biogen Inc. (BIIB) Stock Forecasts - Yahoo Finance
APLS Stock Soars 140% Today – Here’s Everything To Know About Apellis' Massive $5.6B Deal With Biogen - Stocktwits
Hims & Hers Health, Regeneron, Biogen, BioMarin Pharmaceutical, and Moderna Shares Are Falling, What You Need To Know - Yahoo Finance
Biogen Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Biogen (NASDAQ:BIIB) Target Revision Sparks Nasdaq Futures Focus - Kalkine Media
Why Biogen Is Paying $5.6B to Buy Apellis Pharma - MedCity News
H.C. Wainwright raises Biogen stock price target on Apellis deal By Investing.com - Investing.com India
H.C. Wainwright raises Biogen stock price target on Apellis deal - Investing.com
BIIB Analyst Rating: HC Wainwright & Co. Raises Price Target to $237 | BIIB Stock News - GuruFocus
Biogen’s $5.6 Billion Apellis Buy Drives Top Trading Volume Amid Share Price Slide - Bitget
Biogen Acquires Apellis for $5.6B, Shares Dip | Strategic Immunology MoveNews and Statistics - indexbox.io
Biogen, on the heels of a $5.6B buyout, turns its sights to early-stage assets - BioPharma Dive
Canaccord Genuity Raises Price Target for Biogen (BIIB) to $245 - GuruFocus
Mass. companies close major deals in biotech, media in March - The Business Journals
Biogen Inc (BSP:BIIB34) Stock Price, Trades & News - gurufocus.com
Oppenheimer Raises Biogen (BIIB) Price Target to $275, Maintains Outperform Rating | BIIB Stock News - GuruFocus
FDA Approves Higher-Dose Regimen of Nusinersen for Spinal Muscular Atrophy - Pharmacy Times
Biogen’s $5.6bn Apellis Deal Delivers Windfall for Worldwide Healthcare Trust - TipRanks
Biogen to acquire Apellis Pharmaceuticals for $5.6 billion - Investing.com
Biogen to acquire Apellis Pharmaceuticals for $5.6 billion By Investing.com - Investing.com India
Biogen stock is locked into a rising trendline — And $202.41 is the destination - fxstreet.com
Biogen Enters $5.6 Billion Agreement to Acquire Apellis Pharmaceuticals - Pharmaceutical Executive
Biogen to Acquire Apellis for $5.6B to Strengthen Immunology Portfolio - Yahoo Finance
Biogen (NASDAQ:BIIB) Price Target Raised to $191.00 - MarketBeat
Biogen (NASDAQ:BIIB) Given New $275.00 Price Target at Oppenheimer - MarketBeat
Biopharma M&A Heats Up, Rare Diseases Win Three Approvals, Wave Crashes - BioSpace
Biogen (NASDAQ:BIIB) Price Target Raised to $245.00 at Canaccord Genuity Group - MarketBeat
Biogen Inc. stock outperforms competitors on strong trading day - MSN
Canaccord Genuity Adjusts Biogen PT to $245 From $230, Maintains Buy Rating - MarketScreener
Oppenheimer Adjusts Price Target on Biogen to $275 From $250, Maintains Outperform Rating - MarketScreener
Biogen stock price target raised to $245 by Canaccord on Apellis deal - Investing.com
Wedbush Raises Price Target on Biogen to $191 From $187, Keeps Neutral Rating - marketscreener.com
Biogen uplifts rare disease pipeline with $5.6bn Apellis buyout - Yahoo Finance
Apellis Pharmaceuticals to be Acquired by Biogen in Merger - TipRanks
Biogen bolsters immunology offerings with $5.6bn Apellis buy - bioxconomy.com
Apellis Pharmaceuticals (APLS) Hits 2-Year High on 140% Upside from Biogen Merger - Yahoo Finance
Biogen to Acquire Apellis, Expanding Ophthalmology Portfolio - TipRanks
Why Biogen Stock Sank While the Market Soared on Thursday - Yahoo Finance
Biogen strengthens push into nephrology with $5.6B Apellis deal - biocentury.com
Biogen to acquire Apellis Pharmaceuticals for approximately $5.6bn - MLex
Big Drug Companies Hunting for Deals Are Lowering Their Sights - WSJ
Biogen Paying $5.6B For Apellis As 4 Firms Advise - Law360
Biogen to buy Apellis (Nasdaq: APLS) for $41 cash plus CVR upside - Stock Titan
[8-K] BIOGEN INC. Reports Material Event - Stock Titan
Biogen to Buy Apellis for $5.6 Billion to Boost Kidney Franchise - Bloomberg.com
Biogen Agrees $5.6B Apellis Deal as Shares Surge 136% on Announcement - GuruFocus
Biogen Snaps Up $5.6 Billion Deal. Why Shares Fell. - Investor's Business Daily
Biogen Inc. (BIIB) Discusses Proposed Acquisition of Apellis and Strategic Growth ObjectivesSlideshow - Seeking Alpha
Apellis Pharma Skyrockets on Biogen Deal. Is It Too Late to Chase APLS Stock? - Barchart
Biogen's Apellis Deal Addresses Some Revenue Growth Concerns -- Market Talk - Moomoo
Biogen Acquires Apellis: Synergies, Risks, And What The Market Is Missing (NASDAQ:APLS) - Seeking Alpha
Biogen to buy biotech company for $5.6B - The Business Journals
Apellis Stock More Than Doubles on Biogen News. Here’s What to Know. - Barron's
Guggenheim reiterates Buy on Biogen stock after Apellis deal - Investing.com
Market movers: Apellis Pharmaceutical, Unilever, McCormick, Biogen... - Proactive financial news
Biogen (BIIB.US) Plans to Acquire Apellis (APLS.US) for USD5.6 Billion to Expand Rare Disease Portfolio - AASTOCKS.com
Annexon (ANNX) Gains Attention Amid Pharma Deal Activity - GuruFocus
Biogen (NASDAQ:BIIB) Stock Gap Movement Draws Nasdaq Composite Focus - Kalkine Media
Apellis skyrockets 135% after Biogen buyout news - Breakingthenews.net
Biogen (NASDAQ:BIIB) Shares Gap DownHere's Why - MarketBeat
0.81%
1.37%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):